Cited by 85Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerCancer Mechanisms and Therapy

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Targeting Therapies for the p53 Protein in Cancer Treatments

Levine, Arnold J.·2019·Annual Review of Cancer Biology

DOI 10.1146/annurev-cancerbio-030518-055455

Open this paper in CoChat — free account

Abstract

Half of all human cancers contain TP53 mutations, and in many other cancers, the function of the p53 protein is compromised. The diversity of these mutations and phenotypes presents a challenge to the development of drugs that target p53 mutant cancer cells. This review describes the rationale for many different approaches in the development of p53 targeted therapies: ( a) viruses and gene therapies, ( b) increased levels and activity of wild-type p53 proteins in cancer cells, ( c) p53 protein gain-of-function inhibitors, ( d) p53 protein loss-of-function structural correctors, ( e) mutant p53 protein synthetic lethal drugs interfering with the p53 pathway, and ( f) cellular immune responses to mutant p53 protein antigens. As these types of therapies are developed, tested, and evaluated, the best of them will have a significant impact upon cancer treatments and possibly prevention.

Integrity signals

Registry

Crossref · 10.1146/annurev-cancerbio-030518-055455

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“Among the stresses that activate p53 and produce higher levels of transcription are DNA damage (Maltzman & Czyzyk 1984, Kastan et al. 1991), telomere erosion (Karlseder et al. 1999), metabolic alterations (Levine & Puzio-Kuter 2010), hypoxia (Sermeus & Michiels 2011), deficiencies in ribosomal biogenesis (Zhang & Lu 2…”
Background
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Self-citation
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citation
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Self-citation
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · cited 2×
“The X-ray (Cho et al. 1994) and nuclear magnetic resonance structures of the DBD ( Joerger et al. 2005) are known and show a compact structure, with several amino acids that make close contacts with DNA residues (248, 273, and 282) and a set of amino acids that are further away from the DNA and stabilize the overall s…”
Background
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Self-citation
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,097

Show all 87 references

Research works printed but not linked: 6

Kastan MB, 1991, Cancer Res, 51, 6304
Levine AJ, 2010, The P53 Family
Lozano G, 2016, The p53 Protein: From Cell Regulation to Cancer
Peng Z, 2008, IDrugs, 11, 346
Soussi T., 2000, Cancer Res, 60, 1777
Waldman T, 1995, Cancer Res, 55, 5187

Sorted by citations

Targeting apoptosis in cancer therapy
Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,676
p53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 876
Self-citation
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 576
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 355
Sex disparities matter in cancer development and therapy
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B., & Haupt, Y. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00348-y · Cited by 350
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 267
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Chen, S., Wu, J., Liang, Y., Tang, Y., Song, H., Wu, L., Xing, Y., Yan, N., Li, Y., Wang, Z., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.013 · Cited by 250
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
Self-citation
From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
Valdivia, G., Alonso‐Diez, Á., Alenza, M. D. P., & Peña, L. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.623800 · Cited by 126
Apoptosis and Pharmacological Therapies for Targeting Thereof for Cancer Therapeutics
Singh, V., Khurana, A., Navik, U., Allawadhi, P., Bharani, K. K., & Weiskirchen, R. (2022) · Sci · doi:10.3390/sci4020015 · Cited by 102
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 86
Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies
Martinelli, A. H. S., Lopes, F. C., John, E. B. D. O., Carlini, C. R., & Ligabue‐Braun, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061322 · Cited by 99
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
Zhang, S., Carlsen, L., Borrero, L. J. H., Seyhan, A. A., Tian, X., & El‐Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 75
Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils
Yang, D. S., Saeedi, A., Davtyan, A., Fathi, M., Sherman, M. B., Safari, M. S., Klindziuk, A., Barton, M. C., Varadarajan, N., Kolomeisky, A. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015618118 · Cited by 64
TP53 in Biology and Treatment of Osteosarcoma
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 66
Spontaneous and inherited TP53 genetic alterations
Levine, A. J. (2021) · Oncogene · doi:10.1038/s41388-021-01991-3 · Cited by 67
Self-citation
A comprehensive study of p53 protein
Patil, M. R., & Bihari, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30331 · Cited by 57
Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy
Harakandi, C., Nininahazwe, L., Xu, H., Liu, B., He, C., Zheng, Y., & Zhang, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105273 · Cited by 53
Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
Jin, M., Xia, B.-R., Xu, Y., & Jin, W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00598 · Cited by 50
Targeting the P53 Protein for Cancer Therapies: The Translational Impact of P53 Research
Levine, A. J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2709 · Cited by 48
Self-citation
Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead
Jauset, T., & Beaulieu, M.-È. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.03.014 · Cited by 45
Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics
He, W., Yan, J., Li, Y., Yan, S., Wang, S., Hou, P., & Lu, W. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.041 · Cited by 42
Protein conformation and biomolecular condensates
Vazquez, D. S., Toledo, P. L., Gianotti, A. R., & Ermácora, M. R. (2022) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2022.09.004 · Cited by 43
Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence
Sundar, D., Yu, Y., Katiyar, S. P., Putri, J. F., Dhanjal, J. K., Wang, J., Sari, A. N., Kolettas, E., Kaul, S. C., & Wadhwa, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1099-x · Cited by 45
Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance
Berendsen, M. R., Stevens, W. B. C., van den Brand, M., van Krieken, J. H., & Scheijen, B. (2020) · Cancers · doi:10.3390/cancers12123553 · Cited by 40
Dying to Survive—The p53 Paradox
Lees, A., Sessler, T., & McDade, S. S. (2021) · Cancers · doi:10.3390/cancers13133257 · Cited by 38
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110622 · Cited by 37
Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progression
Feng, R., Yin, Y., Wei, Y., Li, Y., Li, L., Zhu, R., Xiao, Y., Liu, Y., Zhao, Y., & Liu, Z. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216154 · Cited by 35
The potential role of miRNAs in the pathogenesis of testicular germ cell tumors - A Focus on signaling pathways interplay
Doghish, A. S., Moustafa, H. A. M., Elballal, M. S., Sallam, A.-A. M., El‐Dakroury, W. A., Mageed, S. S. A., Elesawy, A. E., Abdelmaksoud, N. M., Shahin, R. K., Midan, H. M., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154611 · Cited by 32
Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes
Kallen, J. A., Izaac, A., Chau, S., Wirth, E., Schoepfer, J. G., Mah, R., Schlapbach, A., Stutz, S., Vaupel, A., Guagnano, V., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900201 · Cited by 30
CDK9 inhibitors reactivate p53 by downregulating iASPP
Wu, J., Liang, Y., Tan, Y., Tang, Y., Song, H., Wang, Z., Li, Y., & Lu, M. M. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109508 · Cited by 28
Bayesian Structure Learning in Multilayered Genomic Networks
Ha, M. J., Stingo, F. C., & Baladandayuthapani, V. (2020) · Journal of the American Statistical Association · doi:10.1080/01621459.2020.1775611 · Cited by 26
Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor
Moxley, A. H., & Reisman, D. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3590 · Cited by 25
Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses
Ali, S., Qin, X., Muhammad, T., Liu, L., Meng, X., Bars‐Cortina, D., Khan, A. A., Huang, Y., & Dong, L. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10207-w · Cited by 23
Mathematical Modelling of p53 Signalling during DNA Damage Response: A Survey
Eliaš, J., & Macnamara, C. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910590 · Cited by 21
TP53BP2: Roles in suppressing tumorigenesis and therapeutic opportunities
Huo, Y., Cao, K., Kou, B., Chai, M., Dou, S., Chen, D., Shi, Y., & Liu, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.08.014 · Cited by 19
Interplay between HMGA and TP53 in cell cycle control along tumor progression
Costa, N. M. D., Palumbo, A., Martino, M. D., Fusco, A., Pinto, L. F. R., & Nasciutti, L. E. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03634-4 · Cited by 20
Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02057-8 · Cited by 17
Prognostic Factors After Hepatectomy for Gastric Adenocarcinoma Liver Metastases: Desmoplastic Growth Pattern as the Key to Improved Overall Survival
Temido, M. J., Oliveira, R. C., Martins, R. J. T., Serôdio, M., Costa, B. P., Carvalho, C., Santos, E., Ferreira, L., Teixeira, P., Cipriano, M. A., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s264586 · Cited by 16
TP53-Activated lncRNA GHRLOS Regulates Cell Proliferation, Invasion, and Apoptosis of Non-Small Cell Lung Cancer by Modulating the miR-346/APC Axis
Ren, K., Sun, J., Liu, L., Yang, Y.-P., Li, H., Wang, Z., Deng, J., Hou, M., Qiu, J., & Zhao, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.676202 · Cited by 14
Unravelling the anticancer potential of a square planar copper complex: toward non-platinum chemotherapy
Malik, M. A., Raza, M. K., Mohammed, A., Wani, M. Y., Al‐Bogami, A. S., & Hashmi, A. A. (2021) · RSC Advances · doi:10.1039/d1ra06227a · Cited by 14
Ophiopogonin D increase apoptosis by activating p53 via ribosomal protein L5 and L11 and inhibiting the expression of c-Myc via CNOT2
Ko, H. M., Jee, W., Lee, D., Jang, H.-J., & Jung, J. H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.974468 · Cited by 15
Golgi apparatus targeted therapy in cancer: Are we there yet?
Lee, Z. Y., Lee, W. H., Lim, J. S., Ali, A. A. A., Loo, J. S. E., Wibowo, A., Mohammat, M. F., & Foo, J. B. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122868 · Cited by 15
RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence
Regan, J. L., Schumacher, D., Staudte, S., Steffen, A., Lesche, R., Toedling, J., Jourdan, T., Haybaeck, J., Mumberg, D., Henderson, D. A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102618 · Cited by 17
Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
Yang, Y., Peng, Z., Flores, E. R., & Kleinerman, E. S. (2022) · Cancers · doi:10.3390/cancers14174310 · Cited by 15
Metal-Based Anticancer Complexes and p53: How Much Do We Know?
Alfadul, S. M., Matnurov, E. M., Varakutin, A. E., & Babak, M. V. (2023) · Cancers · doi:10.3390/cancers15102834 · Cited by 15
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed, K., Spiegelberg, D., Kannan, P., Påvénius, L., Hacheney, J., Jiang, L., Eisinger, S., Lianoudaki, D., Lama, D., Castillo, F. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0053 · Cited by 13
Protein nanocondensates: the next frontier
Toledo, P. L., Gianotti, A. R., Vazquez, D. S., & Ermácora, M. R. (2023) · Biophysical Reviews · doi:10.1007/s12551-023-01105-1 · Cited by 15
Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research
Virani, S., Baiocchi, G., Bowtell, D. D. L., Cabasag, C. J., Cho, K. R., Fortner, R. T., Fujiwara, K., Kim, J., Köbel, M., Kurtz, J., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab043 · Cited by 12
Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations
Gil-Ranedo, J., Gallego-García, C., & Almendral, J. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109673 · Cited by 12
Computational quantification of global effects induced by mutations and drugs in signaling networks of colorectal cancer cells
Sommariva, S., Caviglia, G., Ravera, S., Frassoni, F., Benvenuto, F., Tortolina, L., Castagnino, N., Parodi, S., & Piana, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-99073-7 · Cited by 11
The phosphoproteome is a first responder in tiered cellular adaptation to chemical stress followed by proteomics and transcriptomics alteration
Chen, P., Li, Y., Long, Q., Zuo, T., Zhang, Z., Guo, J., Xu, D., Li, K., Liu, S., Li, S., et al. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.140329 · Cited by 10
PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation
Schram, A. M., Fellous, M. M., LeDuke, K., Schmid, A., & Dumbrava, E. E. I. (2025) · Future Oncology · doi:10.1080/14796694.2025.2557176 · Cited by 9
Gain and loss of function mutations in biological chemical reaction networks: a mathematical model with application to colorectal cancer cells
Sommariva, S., Caviglia, G., & Piana, M. (2021) · Journal of Mathematical Biology · doi:10.1007/s00285-021-01607-0 · Cited by 8
D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy
Barra, J., Cerda‐Infante, J., Sandoval, L., Gajardo-Meneses, P., Henriquez, J. F., Labarca, M., Metz, C., Venegas, J., Retamal, C., Oyanadel, C., et al. (2021) · Cancers · doi:10.3390/cancers13143622 · Cited by 6
A Hill type equation can predict target gene expression driven by p53 pulsing
Shi, X. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13179 · Cited by 6
Characterization of the interaction between the tumour suppressor p53 and heme and its role in the protein conformational dynamics studied by various spectroscopic techniques and hydrogen/deuterium exchange coupled with mass spectrometry
Vávra, J., Sergunin, A., Pompach, P., Savchenko, D. V., Hraníček, J., Šloufová, I., Shimizu, T., & Martínková, M. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112180 · Cited by 5
Mesoscopic Liquid Clusters Represent a Distinct Condensate of Mutant p53Preprint
Yang, D. S., Saeedi, A., Davtyan, A., Fathi, M., Safari, M. S., Klindziuk, A., Barton, M. C., Varadarajan, N., Kolomeisky, A. B., & Vekilov, P. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.04.931980 · Cited by 5
A critical review of the synergistic potential of targeting p53 and CAR T cell therapy in cancer treatment
Ashique, S., Debnath, B., Ramzan, M., Taj, T., Islam, A., Chaudhary, P., Kaushik, M., Garg, A., Sen, A., Raveendran, C., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118308 · Cited by 5
Peptide and protein chemistry approaches to study the tumor suppressor protein p53
Chatterjee, C., & Singh, S. K. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob00902a · Cited by 4
Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy
Chaudhary, B., Arya, P., Sharma, V., Kumar, P., Singla, D., & Grewal, A. S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108388 · Cited by 5
Broad-spectrum rescue compounds for structural p53 mutations: perspective on ‘Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site’
Wu, J., Chen, S., & Lu, M. M. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab007 · Cited by 4
Mis-splicing drives loss of function of p53E224D point mutation
Lock, I. C., Leisenring, N. H., Floyd, W., Xu, E. S., Luo, L., Ma, Y., Mansell, E. C., Cardona, D. M., Lee, C., & Kirsch, D. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318856 · Cited by 3
Bayesian Structure Learning in Multi-layered Genomic Networks
Ha, M. J., Stingo, F. C., & Baladandayuthapani, V. (2020) · Figshare · doi:10.6084/m9.figshare.12404486 · Cited by 3
Translational Research in Microbial Healthcare Products with Special Reference to Anticancer Drug Discovery from Actinobacteria
Manikkam, R., Saravanan, T. G., Ranjani, S., Kumar, A. K., Azhagesan, S., Manigundan, K., Gopikrishnan, V., Parthasarathy, K., Shanmugasundaram, T., Sasirekha, S., et al. (2024) · Springer eBooks · doi:10.1007/978-981-97-1777-4_10 · Cited by 2
P53, ROS: Redox Regulation Signaling, Metabolic Reprogramming, and Autophagy in Cancer
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_7 · Cited by 2
Consensus-based somatic variant-calling method correlates FBXW7 mutations with poor prognosis in canine B-cell lymphomaPreprint
White, M. E., Hayward, J. J., Hertafeld, S., Castelhano, M. G., Leung, W., Dave, S., Bhinder, B., Elemento, O., Boyko, A. R., Richards, K. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.16.250100 · Cited by 2
General P53 Signaling Pathway-Related Genes in Cancer
Motalleb, G. (2024) · International journal of basic science in medicine · doi:10.34172/ijbsm.46657 · Cited by 2
Systematic pan-cancer analysis reveals the distinct role of POLE2 expression in cancer prognosis and its interaction with the tumour microenvironment
Ahammad, K., Jihan, A., Akter, S., & Rahman, A. (2025) · Next research. · doi:10.1016/j.nexres.2025.100391 · Cited by 1
D EMOGRAPHIC CHARACTERISTICS OF BASAL CEL L CARCINOMA: A RETROSPECTIVE STUDY OF 1884 LESIONS
Stevanović, G., Janković, I., Paravina, J., Janković, D., & Veličković, M. (2017) · Acta Medica Medianae · doi:10.5633/amm.2017.0321
Nanomedicine for Challenging Solid Tumors: Recent Trends and Future Ahead
Mehta, T. A., Dave, H. V., Shah, J., Hariharan, K., Memon, H., Soni, M., & Johnson, J. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-6255-6_17
Absence of Association Between Serum Mutant p53 with HbA1c and Insulin in Brain Tumor Patients with Type 2 Diabetes Mellitus
Sauriasari, R., Syarif, H., Takhwifa, F., & Aninditha, T. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220519140903
Mesoscopic p53-rich clusters represent a new class of protein condensates
Yang, D. S., Tilson, A., Sherman, M. B., Varadarajan, N., & Vekilov, P. G. (2025) · Biophysics Reviews · doi:10.1063/5.0243722 · Cited by 2
Li-Fraumeni Syndrome-Associated p53 Variants Disrupt Kidney and Urinary Tract DevelopmentPreprint
Romero, A., Davilavaladez, A., Blackburn, A. T. M., Kinua, A. G., Srivastava, Y., Evans, D. G., Bancroft, E. K., Eeles, R. A., Corkins, M. E., & Miller, R. K. (2025) · medRxiv · doi:10.1101/2025.08.29.25333303
Additional file 8 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128586
Additional file 3 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128571
Additional file 1 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128565
Additional file 7 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128583
Additional file 4 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128574
Additional file 6 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128580
Additional file 5 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128577
Additional file 2 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128568
Hereditary cancer syndromes linked to oxidative phosphorylation insufficiency
Kaplan, B., Duraj, T., Lee, D. C., & Seyfried, T. N. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0301
Natural Modulators of the TP53 Pathway: Potential Herbal and Plant‐Derived Agents for Cancer Therapy
Nandi, S., Naskar, A., Khatua, S., Acharya, K., Büsselberg, D., Herrera‐Bravo, J., Arancibia‐Díaz, A., Setzer, W. N., Rotariu, L. S., Dragunescu, A. A., et al. (2026) · Phytotherapy Research · doi:10.1002/ptr.70323

Authors: Levine, A. J.
Affiliations: Institute for Advanced Study (US)
Corresponding author: Levine, Arnold J.
ORCID: Levine, Arnold J.
Venue: Annual Review of Cancer Biology
Publisher: Annual Reviews
Published: 2019-03-04
Volume: 3
Issue: 1
Pages: 21-34
ISSN: 2472-3428 (ISSN-L)
DOI: 10.1146/annurev-cancerbio-030518-055455
OpenAlex: W2883443537
Cited by: 84
References: 87
Citations by year: 2026: 1 · 2025: 8 · 2024: 3 · 2023: 8 · 2022: 12 · 2021: 30 · 2020: 14 · 2019: 6
FWCI: 1.36
Type: journal article
Language: en
Open access: closed
Locations: Annual Review of Cancer Biology (publishedVersion)
Funders: National Institutes of Health
National Cancer Institute
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: p53, TP53 mutation, p53-targeted therapy, synthetic lethality, cancer immunotherapy, oncolytic viruses, gene therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting Therapies for the p53 Protein in Cancer Treatments

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks